The FDA’s approval of Biogen’s Alzheimer’s drug Aduhelm resulted in shares of the biotech rocketing higher – and the rest of the biotech sector went along for the ride. The FDA’s decision, however, is not without significant controversy, so can the upward trend for biotech be expected to continue? Is it time for investors to “say yes to drugs”? CLICK HERE.
Should Investors “Say Yes To Drugs” On Heels Of Biogen Approval?
- by RobH
